{"success":true,"data":{"pressRelease":{"id":"165427","rtpr_id":"nBw9gSl7ca-20261009","ticker":"MEDCL","exchange":"Euronext Paris","all_tickers":["MEDCL"],"title":"Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm","author":"Business Wire","published_at":"2026-10-09T12:58:00.084Z","article_body":"Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as\nof 2:45pm\n\nRegulatory News:\n\nTrading in Medincell shares on Euronext Paris was suspended at the Company's\nrequest as of 9:00 a.m. CEST today, pending the publication of a press\nrelease.\n\nTrading on Euronext Paris will resume on October 9, 2026 at 2:45 pm CEST.\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nThese treatments combine active pharmaceutical ingredients with our\nproprietary BEPO(®) / BEPO(®) Star technologies, which enable controlled\ndrug delivery at therapeutic levels for several days, weeks, or months\nfollowing a subcutaneous or local injection of a small, fully bioresorbable\ndepot.\n\nRisperidone LAI was the first treatment based on BEPO(®) technology to\nreceive FDA approval, initially for schizophrenia in April 2023 (one- and\ntwo-month dosing), and subsequently for Bipolar I Disorder in October 2025\n(one-month dosing). It is marketed in the United States by Teva under the\nbrand name UZEDY(®).\n\nOlanzapine LAI as a once-monthly treatment for schizophrenia in adults\nreceived FDA approval in October 2026 with launch in the United States by Teva\nunder the brand name WELTRUZA(™) planned in Q4 2026. A European Marketing\nAuthorization Application (MAA) for Olanzapine LAI was also accepted by EMA in\nMay 2026.\n\nMedincell’s investigational pipeline includes numerous innovative\ntherapeutic candidates in various stages of development, from formulation to\nPhase 3 clinical trials. We collaborate with leading pharmaceutical companies\nand foundations to advance global health through new treatment options.\n\nHeadquartered in Montpellier, France, Medincell employs over 150 people\nrepresenting more than 27 nationalities.\n\nmedincell.com\n\nUZEDY(®) and WELTRUZA™ are trademarks of Teva Pharmaceuticals.\nMedincell’s BEPO(®) technology is licensed to Teva as SteadyTeq™, a\ntrademark of Teva Pharmaceuticals.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261009703707/en/\n(https://www.businesswire.com/news/home/20261009703707/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\nNicolas Mérigeau / Gaëlle Fromaigeat \n\nMedia Relations\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\nLouis-Victor Delouvrier / Alban Dufumier \n\nInvestor Relations France\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw9gSl7ca-20261009","title":"Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as of 2:45pm","author":"Business Wire","ticker":"MEDCL","created":"2026-10-09T12:58:00.084Z","tickers":["MEDCL"],"exchange":"Euronext Paris","article_body":"Medincell Announces Resumption of Trading in Its Shares on Euronext Paris as\nof 2:45pm\n\nRegulatory News:\n\nTrading in Medincell shares on Euronext Paris was suspended at the Company's\nrequest as of 9:00 a.m. CEST today, pending the publication of a press\nrelease.\n\nTrading on Euronext Paris will resume on October 9, 2026 at 2:45 pm CEST.\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nThese treatments combine active pharmaceutical ingredients with our\nproprietary BEPO(®) / BEPO(®) Star technologies, which enable controlled\ndrug delivery at therapeutic levels for several days, weeks, or months\nfollowing a subcutaneous or local injection of a small, fully bioresorbable\ndepot.\n\nRisperidone LAI was the first treatment based on BEPO(®) technology to\nreceive FDA approval, initially for schizophrenia in April 2023 (one- and\ntwo-month dosing), and subsequently for Bipolar I Disorder in October 2025\n(one-month dosing). It is marketed in the United States by Teva under the\nbrand name UZEDY(®).\n\nOlanzapine LAI as a once-monthly treatment for schizophrenia in adults\nreceived FDA approval in October 2026 with launch in the United States by Teva\nunder the brand name WELTRUZA(™) planned in Q4 2026. A European Marketing\nAuthorization Application (MAA) for Olanzapine LAI was also accepted by EMA in\nMay 2026.\n\nMedincell’s investigational pipeline includes numerous innovative\ntherapeutic candidates in various stages of development, from formulation to\nPhase 3 clinical trials. We collaborate with leading pharmaceutical companies\nand foundations to advance global health through new treatment options.\n\nHeadquartered in Montpellier, France, Medincell employs over 150 people\nrepresenting more than 27 nationalities.\n\nmedincell.com\n\nUZEDY(®) and WELTRUZA™ are trademarks of Teva Pharmaceuticals.\nMedincell’s BEPO(®) technology is licensed to Teva as SteadyTeq™, a\ntrademark of Teva Pharmaceuticals.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261009703707/en/\n(https://www.businesswire.com/news/home/20261009703707/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\nNicolas Mérigeau / Gaëlle Fromaigeat \n\nMedia Relations\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\nLouis-Victor Delouvrier / Alban Dufumier \n\nInvestor Relations France\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-09T12:58:00.116771106Z","server_sent_at_ms":1791550680116},"received_at":"2026-10-09T12:58:00.166Z","source_url":"https://www.businesswire.com/news/home/20261009703707/en/"},"analysis":{"id":"153820","press_release_id":"165427","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Same-day trading suspension pending news -- associated announcement not included in this release"],"eventType":"other","narrative":"Medincell said trading in its shares on Euronext Paris, suspended at its own request at 9:00 a.m. CEST, will resume at 2:45 pm CEST on October 9, 2026.\n\nThe suspension was pending publication of a press release, which this notice does not contain.\n\nThe release's background section highlights the October 2026 FDA approval of Olanzapine LAI (WELTRUZA) with a Teva-led U.S. launch planned for Q4 2026, likely the subject of the pending announcement.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Trading resumes after intraday halt; watch for the pending press release as the actual news event."},"keyFigures":{"customDimensions":{"suspension_time":"9:00 a.m. CEST, October 9, 2026","trading_resume_time":"2:45 pm CEST, October 9, 2026"}},"namedEntities":{"people":[{"name":"David Heuzé","role":"Head of Corporate and Financial Communications, and ESG"},{"name":"Grace Kim","role":"Chief Strategy Officer, U.S. Finance"}],"products":["UZEDY","WELTRUZA","Risperidone LAI","Olanzapine LAI","BEPO","SteadyTeq"],"companies":[{"name":"Medincell","ticker":"MEDCL","relationship":"filer"},{"name":"Teva Pharmaceuticals","relationship":"partner/marketer"},{"name":"Euronext Paris","relationship":"exchange"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a procedural notice that trading resumes after a same-day suspension pending a press release; no new financial or clinical facts are disclosed. The underlying announcement is not included here."},"tickerRelevance":{"others":[],"primary":"MEDCL"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"procedural-trading-resume","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Medincell said trading in its shares on Euronext Paris, suspended at its own request at 9:00 a.m. CEST, will resume at 2:45 pm CEST on October 9, 2026.\n\nThe suspension was pending publication of a press release, which this notice does not contain.\n\nThe release's background section highlights the October 2026 FDA approval of Olanzapine LAI (WELTRUZA) with a Teva-led U.S. launch planned for Q4 2026, likely the subject of the pending announcement.","key_figures":{"customDimensions":{"suspension_time":"9:00 a.m. CEST, October 9, 2026","trading_resume_time":"2:45 pm CEST, October 9, 2026"}},"named_entities":{"people":[{"name":"David Heuzé","role":"Head of Corporate and Financial Communications, and ESG"},{"name":"Grace Kim","role":"Chief Strategy Officer, U.S. Finance"}],"products":["UZEDY","WELTRUZA","Risperidone LAI","Olanzapine LAI","BEPO","SteadyTeq"],"companies":[{"name":"Medincell","ticker":"MEDCL","relationship":"filer"},{"name":"Teva Pharmaceuticals","relationship":"partner/marketer"},{"name":"Euronext Paris","relationship":"exchange"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T12:58:06.062Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"small-cap","eventGravity":"procedural-trading-resume","issuerAuthored":true}},"durationMs":5884,"modelName":"glm-5.3-flashx"}}